데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
52-49-3OC(CC[NH+]1CCCCC1)(c1ccccc1)C1CCCCC1.[Cl-]QDWJJTJNXAKQKD-UHFFFAOYSA-N52-49-3Benzhexol hydrochloride is White Solid
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Trihexyphenidyl is an antagonist of M1 muscarinic acetylcholine receptors. It binds to rat M1 receptors in cerebral cortex selectively over rat M2 receptors in heart tissue (IC50s = 3.7 and 31 nM, respectively). Trihexyphenidyl inhibits contractions induced by acetylcholine in guinea pig ileum (IC50 = 22 nM). It also inhibits oxotremorine-induced tremors and physostigmine-induced mortality in mice (ED50s = 2 and 3.6 mg/kg, respectively). Trihexyphenidyl (20 mg/kg) improves abnormal movement in a mouse model of L-3,4-dihydroxyphenylalanine (L-DOPA) responsive dystonia (DRD) that expresses mutant tyrosine hydroxylase (TH). Formulations containing trihexyphenidyl have been used in the symptomatic treatment of Parkinson''s disease.
용도Benzhexol hydrochloride is an anticholinergic tertiary amine that can gain access to the CNS. It is used to treat parkinsonism and the extrapyramidal side effects of anti-psychotic drugs. The drug is a muscarinic anta gonist that qualitatively resembles the belladonna alkaloids in its pharmacological actions and side effects.
일반 설명Trihexyphenidylhydrochloride, α-cyclohexyl-α-phenyl-1-piperidinepropanolhydrochloride (Artane, Tremin, Pipanol), introduced in1949, is approximately half as active as atropine as an antispasmodicbut is claimed to have milder side effects, such asmydriasis, drying of secretions, and cardioacceleration. It hasa good margin of safety, although it is about as toxic as atropine.It has found a place in the treatment of parkinsonismand is claimed to provide some measure of relief from themental depression often associated with this condition. It does, however, exhibit some of the side effects typical of theparasympatholytic-type preparation, although adjusting thedose carefully may often eliminate these.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…